- BioCryst Pharmaceuticals (NASDAQ:BCRX) on Monday announced the appointment of Babar Ghias as chief financial officer and head of corporate development.
- Ghias joins BioCryst from AvenCell Therapeutics, where he served as CFO since 2022.
- Previously, Ghias was executive vice president of investments
BioCryst appoints Babar Ghias as CFO

Related
Almonty files for Nasdaq listing
9 minutes ago
0
Liberty All-Star Equity raises dividend by 20% to $0.18
11 minutes ago
0
Another of Putin’s ministers allegedly commits suicide—he wa...
21 minutes ago
0
SEC requests Solana ETF refilings by end-July, opening door ...
24 minutes ago
0
Market Voices: Tariff deadline moved to Aug. 1, Trump threat...
30 minutes ago
0
Datavault AI acquires SyncIN Technology from Turner Global M...
32 minutes ago
0
Sinclair appoints Narinder Sahai CFO, Lucy Rutishauser to re...
36 minutes ago
0
S&P Dow Jones Indices reports slowdown in U.S. dividend grow...
38 minutes ago
0
Ante up: Trump’s budget bill stacks the cards against gamble...
38 minutes ago
0
Chef Boyardee’s founder sold the brand for $6 million in 194...
46 minutes ago
0
Dollar inches higher ahead of Trump’s trade deadline-Currenc...
47 minutes ago
0
Bit Digital soars 30% after moving entire treasury to Ethere...
52 minutes ago
0
Eni, Algeria's Sonatrach sign $1.35B production sharing deal...
58 minutes ago
0
Today’s bull market has just begun – UBS
1 hour ago
0
Trending
Popular
© FBT Company 2025. All rights are reserved